Target intelligence / Profile preview

Vacuolating cytotoxin A (VacA)

Target
VacA
Molecular classification
Bacterial toxin, Pore-forming protein, Autotransporter protein
01

Overview

Vacuolating cytotoxin A (VacA) is a potent exotoxin and major virulence factor secreted by the bacterium Helicobacter pylori, which colonizes the human stomach (UniProt P14739). The protein is synthesized as a large precursor that undergoes proteolytic processing to produce p33 and p55 subunits, which subsequently form high-molecular-weight oligomeric complexes (Cover & Blanke, 2005). These complexes insert into host cell membranes to create anion-selective channels, leading to the formation of large, acidic vacuoles and the disruption of endolysosomal trafficking (McClain et al., 2003). Beyond vacuolation, VacA induces mitochondrial damage, triggers apoptosis, and suppresses the immune response by inhibiting T-cell proliferation and activation (Palframan et al., 2012). Because of its critical role in the pathogenesis of gastric ulcers and gastric cancer, VacA is a primary target for the development of neutralizing antibodies, vaccines, and therapeutic inhibitors (Foegeding et al., 2016).

Other names
Vacuolating cytotoxin autotransporterVacuolating cytotoxinVacA proteinHelicobacter pylori VacA
02

Mechanism of action

Neutralization of toxin activity by blocking pore formation, inhibiting cell binding, or preventing the oligomerization of p33 and p55 subunits (Yahiro et al., 2015; Palframan et al., 2012).

03

Biological functions

Cellular vacuolationApoptosisMembrane pore formationInhibition of T-cell activationMitochondrial dysfunctionSignal transductionImmune response modulation
04

Disease associations

GastritisPeptic ulcerGastric adenocarcinomaInfectionMALT lymphoma
05

Safety considerations

High genetic variability (polymorphism) between H. pylori strainsChallenges in achieving sustained mucosal immunityIntracellular localization makes targeting difficult once toxin is internalized
06

Interacting drugs

Bismuth subsalicylate

3 more in the full profile.

07

Biomarkers

Anti-VacA antibodiesvacA genotype (e.g., s1/m1 vs s2/m2 types)

Beyond the preview

Go deeper on Vacuolating cytotoxin A (VacA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vacuolating cytotoxin A (VacA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call